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Autoradiographic localization of vasopressin and oxytocin binding sites
in rat kidney. The presence of vasopressin receptors of the V1 (vascu-
lar) type and of oxytocin receptors in the rat kidney was investigated
using an autoradiographical approach. Rat kidney sections were incu-
bated with tritiated vasopressin ([3Hjvasopressin, 1.5 aM) or oxytocin
([3H]oxytocin, 3 nM). The ligand selectivity of the FH]vasopressin
binding sites detected was deduced from competition experiments using
one selective unlabeled ligand for V2 (antidiuretic) vasopressin recep-
tors (l-deamino-8-D-arginine]-vasopressin, dDAVP) and one selective
unlabeled ligand for V1 receptors (des-glycineamide-[l-i-mercapto-13,
-cyclopentamethylene propionic acidi-arginine vasopressin, des(Gly
(NH2)9d(CH2)AVP). Specific and dense [31-l]vasopressin labeling was
observable in the medullopapillary and cortical portions of the kidney.
Specific [3H]vasopressin binding in the cortex was insensitive to the
V1-selective ligand, des(Gly(NH')9d(CH2h-AVP, hut was inhibited by
dDAVP. Glomerular structures identified as such by microscopical
observation of the kidney sections were specifically labeled with
l3H]oxytocin and ['25lj-SAR'-angiotensin 11 but not with l7Hlvasopres-
sin, It is concluded that V1 receptors which have been evidenced on
mesangial cells in culture are not expressed in a detectable quantity on
mesangial cells in situ. The specific l3H]oxytocin binding to glomeruli
might reflect the presence on glomerular structures of oxytocin recep-
tors involved in the effects of the hormone on renal hemodynamics, and
possibly in some of the effects ascribed to vasopressin.
Vasopi-essin, the antidiuretic hormone in mammals, pro-
motes water and solute reabsorption by the kidney. Micropunc-
ture and microperfusion studies, on the one hand, and determi-
nation of vasopressin-sensitive adenylate cyclase activity in
single and anatomically-defined tubular segments, on the other
hand, allowed the identification of the vasopressin-sensitive
segments along the nephron [reviewed in 11. These studies
clearly established that: I) vasopressin is active cm the medul-
lary and cortical portions of the collecting duct and on the large
ascending limb of the loop of Henle. The latter site of action
could be demonstrated in several (including the rat) hut not all
mammalian species so far studied. 2) The tubular effects of
vasopressin are mediated by a V2 type of vasopressin receptor,
that is, adenylate cyclase-coupled receptors as opposed to
phospholipase C-coupled V1 receptors [21.
It has been suggested that besides tubular cells, other vaso-
pressin-sensitive cells might exist in the mammalian kidney.
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especially in glomeruli, medullary interstitium and renal vascu-
lature. In vivo administered vasopressin reduces the glomerular
capillary ultrafiltration coefficient which results in the decrease
of glomerular filtration rate [3]. It has been suggested that these
effects of exogeneous vasopressin might be a consequence of a
vasopressin-induced contraction of mesangial cells [reviewed in
4, 5]. There is also evidence that vasopressin increases prosta-
glandin synthesis in vivo [6, 7]. In vitro glomerular production
of PGE2 is increased in Brattleboro rats compared to that
observed in Long-Evans rats 181. It was demonstrated that
glomerular mesangial cells in primary and secondary cultures
respond to vasopressin by contraction [9] and increased pros-
taglandin synthesis [10, II]. Vasopressin receptors on glomer-
ular mesangial cells are very likely of the V1 type. Indeed.
vasopressin induces a time- and concentration-dependent in-
crease in inositol phosphate production by mesangial cells, but
fails to alter the adenylate cyclase activity of membranes
derived from these cells [12, 131. Vasopressin analogues with
enhanced selectivity for V2 receptors were found to be poorly
active on mesangial cells [12]. Finally, direct binding studies
revealed the presence of vasopressin receptors on mesangial
cell membranes, the ligand specificity of which resembles that
of previously well characterized V1 vasopressin receptors [13].
The main purpose of the present work was an attempt to
demonstrate by a combined autoradiographical and pharmaco-
logical approach the presence ofV1 vasopressin receptors in the
rat kidney. The presence of vasopressin receptors in glomerular
(and possibly in other extratubular) structures in situ has not
been demonstrated so far.
Since there is also evidence that oxytocin influences renal
hemodynamics as well as electrolyte and water excretion [14—
17], the distribution of specific oxytocin binding sites in the
kidney was also investigated. A preliminary report by Stoeckel
et al [18] indicates the presence of such sites.
Methods
Materials'
Tritiated vasopressin ([3HlPhe3)-arginine vasopressin ([3H]
vasopressin, 64 Ci/mM) and ([3H]Tyr2)-oxytocin ([3H]oxytocin,
36.6 Ci/mM) were purchased from New England Nuclear (Bos-
ton, Massachusetts, USA). The two labeled peptides were
purified before use by HPLC and affinity chromatography on a
neurophysin-Sepharose column as described [19]. Arginine
vasopressin (AVP) and oxytocin were purchased from Bachem
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Vasopressor Antidiuretic
activity activity
Peptide U/mg U/mg
AVP 369" 32V
dDAVP 0.39" 1200"
desGly(NH2)9-d(CH)5-AVP pA2 — 7.96k
—
o.o4
Abbreviations are: AVP, arginine vasopressin; dDAVP, 1-deamino-
[8-D-Argininel-vasopressin: desOly(NH2)9d)CI-t2)5AVP, 9-des glycina-
mide-[ 1-tj3-mercapto-f3j3-cyclopentamethylene propionic acid]-arginine
vasopressin.
a Values are taken from [33].
In vivo antivasopressor activity is isicasured by the pA value, i.e..
the negative logarithm of the molar concentration of antagonist that
reduces the response to 2x units of agonist (AVP) to equal the response
to lx unit of agonist in the absence of antagonist 1341. in vivo pA2 are
estimated from the effective dose divided by an assumed volume of
distribution in the rat of67 mI/kg [35]. The ED. is the dose of antagonist
(in nmol/kg) which reduces the response to 2x units of agonist to equal
the response to one lx unit of agonist administered in the absence of
antagonist. Values are taken from 1361.
Fine Chemicals (Bubendorf, Switzerland) and l-deamino-[8-D-
arginine]-vasopressin (dDAVP) from Ferring (MalniO, Swe-
den). The vasopressin antagonist, dcs-glycineamide-l I -(-mer-
capto-fl,fl-cyclopcntamct hylene propionic acid]-arginine vaso-
pressin (desGly(NH2)9d(CHf,AVP) was from the Medical Col-
lege of Ohio (Toledo. Ohio, USA). 1 he angiotensin analogue
11 -Sarcosinel-angiotensin II (Sar-All) was radioiodinated using
iodogen as the oxydizing agent and the monoiodinated deriva-
tive separated by HPLC as described 1201.
Autoraclio 'rap/iv
Adult male rats of Sprague-Dawley derived stock were used
for this study. They were sacrificed by decapitation. The
kidneys were rapidly removed and frozen in isopentane at
25°C. Longitudinal sections (15 jim) crossing the tip of the
papilla were cut, thaw mounted on chromc/alun/gclatin-coated
slides, dried for 2 to 12 hours in a dessicator at 4°C and stored
at —80°C until use.
Sections were preincubated for 20 minutes by dipping the
slides in 50 m Tris-HCI pH 7.4. 100 mxi NaCI, and 50 trsi OTP
in order to dissociate endogeneous vasopressin which might
have remained bound to vasopressin receptors lie sections
were rinsed twice for five niinutes in so mrvi Tris-HCI. pH 7.4.
Incubation was carried out for one hour in a humid chamber by
covering each section with 100 to 20t) j.d of an incubation
medium composed of ¶0 mrvt Tris-HC'l, 5 mst, MgCh, 0.1 m
hacitracine. 0.17/ bovin serum albumin, and 1.5 isi [31-l]vaso
pressin. Adjacent sections were incubated with [3Hivasopressin
1.5 nro) and 5, 2)), or 10(1 nsi of the unlabeled vasopressin
analogues tised (Table I). Non-specific binding was determined
in the presence of 10 jiM unlabeled vasopressin. Incuhation was
followed by two five minute washes in ice cold incubation
medium without the labeled ligand and a quick rinse in distill-
ated water. The slides were then dried with a cold air stream.
placed for two hours in a vacuum dessicator containing para-
formaldehyde preheated at 80°C to insure fixation, and then
placed in an X-ray cassette in contact with trititim sensitive
LKB ultrolilm during four months. Films were developed for
live minutes in D19 (Eastman Kodak, Rochester, New York,
USA) and the sections were stained with cresyl violet. Similar
experiments were conducted using 3 met flH]oxytocin as the
labeled ligand and 10 j.rM unlabeled oxytocin for estimation of
non-specific binding.
Control experiments were performed with [ilSllSarAll. In-
deed, the presence of specific angiotensin binding sites in the
glomerulus has been previously evidenced by both direct bind-
ing assays and autoradiographic techniques [reviewed in 21].
For these experiments. sections were preineubated for 15 mm
by dipping the slides in 10 m sodium phosphate buffer pH 7.4.
120 mM NaCI. 5 mrvt EDTA, 0. I mM bacitracine, and 2 mg/mI
bovine sertim albumin. Incubation was carried out for one hour
in a humid chamber by covering each section with 100 to 200 ,rd
of the same incubation medium containing 0.05 met I i2S1jSarAll
Nonspecific binding was measured in the presence of I trm
unlabeled Sar-All. Further steps were as described above except
that autoradiograms were developed after 2 to 4 weeks exposure.
Results
Figure I shows autoradiograms obtained from kidney sec-
tions incubated with 1.5 met [2H]vasopressin in the absence or
presence of unlabeled vasopressin 10 jiM. As expected a dense
labeling was observable in the medullopapillary portion of the
kidney. The cortical portion was also labeled although less
intensively (Fig. IA). In both the cortex and medulla [3H]
vasopressin binding was specific and could he entirely displaced
by unlabeled vasopressin (Fig. IB). Examination of the cresyl
violet-stained material on the section used for autoradiography
and adjacent sections indicated that the glomeruli sections
which could be identified as such were not labeled by vasopres-
sin although dense labeling was frequently found in close
vicinity to glomerular structures (compare Figs. IC and ID).
The distribution of HS1]SarAIl binding sites was strikingly
different from that of [l I]vasopressin binding sites (compare
Figs. i and 2). In the cortex. [111]-Sar-AlI-Iaheled structures
appeared mostly as patches sshich clearly corresponded to
glomeruli (compare Figs. 2C and 2D). A specific labeling with
I i2S11 Sar All was also observable in the outer medulla.
In order to more easily detect [3Hlvasopressin binding to V1
vasopressin receptors, competition experiments using selective
unlabeled ligands were performed. Figrire 3 shows autoradi-
ograms obtained from adjacent sections incubated in the pres-
ence of a constant amount of [1Hlvasopressin (1.5 nM) and
increasing concentrations (5. 20, and 100 nM) of either a
selective ligand for V2 receptors )dDAVP) or a selective ligand
for V1 receptors tdesGly(NH1)9d)CH1)2AVP). As indicated in
Table 2 one can estimate that for a [Hlvasopressin eoneentra-
hon of 1.5 n about 607/ of Vi and 68% of V2 vasopressin
receptors present on the section should have been labeled.
More important one can also estimate that in the presence of
dDAVP up to a concentration of 20 met the specific binding to V
receptors would be only slightly inhibited, while specific bind-
ing to V1 receptors would he almost completely inhibited at all
dDAVP concentrations used. Conversely, a 80% inhibition of
PHivasopressin binding to Vi receptors is expected with des-
Gly)NH1)'d(CH25AVP at 100 n while binding to V. receptors
will he slightly affected. As shown in Figure 3. there was no
clearly detectable dDAVP-resistant specific [3H]vasopressin
binding in the cortex, in particular at the level of glomerular
Table 1. Biological activities of vasopressin analogues
which were used
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Fig. 1. Localization of f3HJvasopressin binding sites. A. Autoradiogram obtained from a kidney section incubated in the presence of
[3Hjvasopressin (1.5 nM). B. Autoradiogram obtained from the adjacent section incubated in the presence of 13H]vasopressin (1.5 nM) and 10 /.LM
unlabeled vasopressin. C. Higher magnification of the cortical portion outlined on the autoradiogram shown in A. D. Photomicrograph of cresyl
violet staining of the same area shown by autoradiography in C. Calibration bars : 2 mm Ten identical experiments were performed which gave
similar results.
Fig. 2. Localization of['251J-Sar-A/l binding sites. A. Autoradiogram obtained from a kidney section incubated in the presence of['251J-Sar-AlI (0.05
nM). B. Autoradiogram obtained from the adjacent section incubated in the presence of [1251]-Sar-All (0.05 nM) plus I /LM unlabeled Sar-All. C.
Higher magnification of the cortical portion outlined on the autoradiogram shown in A. D. Photomicrograph of cresyl violet staining of the same
area shown by autoradiography in C. Calibration bars : 2 mm. Six identical experiments were performed which gave similar results.
B
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Fig. 3. Pharmacological characterization of [H] casopressinbinding sites. A, D, G. Autoradiograms obtained from kidney sections incubated in
the presence of [3H]vasopressin (1.5 nM). B, E, H. Autoradiograms obtained from adjacent sections incubated in the presence of (1.5 nM)
[31-I]vasopressin and 5(B), 20(E) or 100 nst (H) desGly(NH2)9d(CH2)ç-AVP. C, F. I. Autoradiograms of adjacent sections incubated in the presence
of[3fllvasopressin (1.5 nM) plus 5(C), 20(F) or 100 nM (I) dDAVP. Calibration bars 2mm. Three identical experiments were performed which
gave similar results.
structures (Figs. 3 C, F, and 1). A slight residual binding of the
medulla was still apparent in the presence of 100 nM dDAVP.
However, this binding could not be attributed to well defined
anatomical structures. Conversely (Fig. 3 B, E, and H) there
was no indication for the presence of any [3H]vasopressin
binding which was selectively sensitive to inhibition by desGly
(NH,)9d(CH2)AVP.
A specific 3Hjoxytocin binding could be evidenced in the
cortical portion of the kidney (Fig. 4). The distribution of the
cortical [3H}oxytocin binding sites resembled that found for
['2I]-Sar-All. Direct microscopical observation of the section
indicated that most of the labeled patches corresponded to
glomeruli (compare Figs. 4C and 4D). However, not al! glomer-
ular structures were found labeled with [3H]oxytocin.
Discussion
The present work constitutes a further confirmation of the
validity of the autoradiographical approach for investigating the
distribution of specific receptors within highly heterogeneous
structures like the mammalian kidney. Autoradiograms of [3H}
vasopressin-labeled kidney sections have already been pub-
lished 1221. However, it was in most instances as control
experiments for studies devoted to autoradiographic localiza-
tion of vasopressin receptors in the brain. To our knowledge,
the present work is the first combined autoradiographical and
pharmacological analysis of the distribution of vasopressin
receptors in the rat kidney. Although the technique used did not
allow localization of the labeled material at a cellular level, it
seems reasonable to conclude that all the tubular segments
which are sensitive to vasopressin (medullary and cortical
collecting ducts and large ascending limbs of the loops of Henle)
were specifically labeled with [3lllvasopressin. It is also clear
that in both the cortical and inedullary portions, specific [3Hj
vasopressin binding occurred at sites which have the expected
ligand specificity of V vasopressin receptors. Indeed, it could
be inhibited by the highly selective V agonist (dDAVP) and
was insensitive to a selective V1 ligand (desgly(NH2)9d(CH2)
AVP). Parallel experiments on brain V1 vasopressin receptors
were performed under identical experimental conditions with
respect to the batches and concentrations of t3Hlvasopressin
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and desgly(NH2)9d(CH2)5AVP which were used. The results
obtained (to be reported elsewhere) indicated that the V1
antagonist do inhibited [3H]vasopressin binding to V1 receptors
as it was detected by autoradiography.
Previous pharmacological studies using selective Vi and V2
ligands failed to reveal heterogeneity in the population of
[3H]vasopressin binding sites present in crude membrane prep-
arations from the cortical or medullopapillary portions of the rat
kidney [23, 271. These studies clearly indicated that the major
population of vasopressin receptors in the kidney is of the V2
subtype. They obviously did not exclude the possibility that a
minor population of V1 receptors was also present hut could not
be detected using this indirect approach. It is also possible that
the procedure used for membrane preparation, which involved
successive centrifugation steps, had eliminated the structures
(blood vessels, glomeruli) or cell types (medullary interstitial
cells) which are putative targets for V1 receptor-mediated
responses to vasopressin. The autoradiographical approach
developed in the present study does not suffers from the latter
limitation. Therefore, we favor the conclusion that V1 receptors
in the kidney are far less numerous than V2 receptors. A labeled
and highly selective ligand for V1 receptors would lower the
detection limit for a minor population of V1 receptors in the
presence of a large excess of V2 receptors. Unfortunately such
a ligand is not presently available. Despite the above limita-
tions, the most puzzling observation derived from the present
study was the absence of any detectable labeling of glomerular
structures with [3Hlvasopressin. If the data obtained on mesan-
gial cells in primary culture [131 are transposable to mesangial
cells in intact glomeruli, the presence of specific vasopressin
binding sites on these cells should have been detected in the
experimental conditions used:
1.) The maximal vasopressin binding capacity of membranes
derived from mesangial cells in culture was found to be 270
fmol/mg protein [13]. This value is high enough to allow
detection by autoradiography. It is in the range of those
reported for several vasopressin-sensitive cells such as rat
hepatocytes [24], rat aortic myocytes [25] and the pig kidney
cell line LLCPKI [26]. It is much higher than the maximal
binding capacity determined on membranes derived from the
entire rat kidney cortex [27]. In fact a specific binding in the
cortex was detected which very likely corresponded to vaso-
pressin binding to cortical collecting ducts but not to glomerular
structures.
2.) The possibility that [3H]vasopressin binding to V1 recep-
tors in the cortex should have been masked by a more intense
labeling of V2 receptors can be reasonably excluded. No
residual specific binding was detected in experimental condi-
tions where binding to V2 receptors was selectively and almost
completely inhibited by dDAVP.
3.) The fact that glomerular labeling with ['251!-Sar-All and
[3H]oxytocin could be easily detected indicates that glonierular
structures in the kidney sections prepared for autoradiography
are accessible to peptides of the size of vasopressin.
4.) The possibility that V1 receptors might be more suscepti-
ble than V2 receptors to inactivation or degradation during the
procedure used for preparation of autoradiograms seems un-
likely. V1 receptors could be easily detected by autoradi-
ography in other vasopressin-sensitive tissues (brain and adeno-
hypophysis, for instance; not shown).
Table 2. Binding characteristics of vasopressin and analogues
Dissociation constants (nM) for
binding by peptide
V1 receptors from V2 receptors from
mesangial cell medullopapillary
Peptide membranes membranes
AVP l.oa
dDAVP 79C
desGly(NH219-d(CH2)5-AVP I0' 324'
Expected inhibition of
[3HJvasopressin (1.5 nM) binding by
unlabeled peptide
Unlabeled peptide
dDAVP
V1 receptors V2 receptors
5 flM 25d 92.2
20 nM 9.2 97.9
100 nM 33.6 99.6
desGly(NH2)9-d(CH2)5-AVP
5 flM 16.7 0.9
20 nM 44.4 3.5
100 tIM 80.0 15.4
C Values taken from [13]b Values taken from [23]
C Values taken from Jard S. (unpublished observations)d % inhibition calculated as 100 x [I — (H + Kd)I[H + Kd(1 + (1/
K1))]] in which H and I are the concentrations of [3H]vasopressin (3.5
nM) and unlabeled peptide, respectively, and Kd and K, the correspond-
ing dissociation constants. Numerical values are those given in the
Table.
It is tempting to conclude that, if present on mesangial cells in
situ, vasopressin receptors are far less abundant than on
mesangial cells in primary culture. It is worth noting that
vasopressin stimulates the growth of several cell types: 3T3
fibroblasts [281, hepatocytes [29], and adrenal cells from the
glomerulosa zone [30]. In addition, it was reported [31, 32] that
fetal calf serum, insulin, and other growth factors increase the
number of vasopressin receptors present at the surface of
LLCPKIL renal cells. The possibility must therefore be con-
sidered that the expression of vasopressin receptors of the V1
type on mesangial cells in culture is markedly enhanced by
growth stimulation.
The observation that [3H]oxytocin binding sites are present in
rat kidney glomeruli deserves special comments. At variance
with the results obtained with [1251]-Sar-All not all glomerular
structures on the sections which were examined were found
labeled with [3H]oxytocin. This might indicate that the two
peptides bind to different cells types and that oxytocin binding
sites are present on structures distinct from, but closely asso-
ciated with glomeruli. The role of oxytocin on renal hemody-
namics, GFR and sodium excretion has been under investiga-
tion for many years (reviewed in 14—16). A recent study by
Conrad et al [17] clearly showed that, in both Long Evans and
Brattleboro rats, oxytocin promotes natriuresis and an increase
in GFR without altering RPF. In the experiments described by
these authors, oxytocin was infused intravenously in conscious
euvolemic animals. The rates of oxytocin infusion which were
used resulted in plasma concentrations of hormone below those
needed to elicit an antidiuretic response through activation of
vasopressin receptors by oxytocin, The authors concluded from
their studies that the observed effect of oxytocin on GFR
B.•;.;-
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Fig. 4. Localization of [3 Fljoxytocin binding sites. A. Autoradiogram of a kidney section incubated in the presence of [3H]oxytocin (3 nM). B.
Autoradiogram of an adjacent section incubated in the presence of [3H}oxytocin (3 nM) and 10 sM unlabeled oxytocin. C. Higher magnification of
the cortical portion outlined on the autoradiogram shown in A. D. Photomicrograph of cresyl violet staining of the same area shown by
autoradiography in C. Calibration bars: 2 mm. Two identical experiments were performed which gave similar results.
reflects a direct action of the hormone on glomerular function.
Two mechanisms have been proposed: 1) a simultaneous de-
crease in preglomerular resistance and increase in postglomer-
ular resistance; and 2) a direct or indirect effect on mesangial
cells causing an increase in ultrafiltration coefficient. It is
tempting to suggest that the [3Hjoxytocin binding sites which
have been evidenced in the present study are functional recep-
tors mediating the effects of oxytocin on glomerular function.
The possibility that some of the glomerular effects ascribed to
vasopressin [3—51 might result from activation by vasopressin of
glomerular oxytocin receptors should also be considered.
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